Patheon IPO finds robust demand

摘要

Shares in contract drug maker patheon opened 19% above their IPO price on Thursday, having earlier priced towards the upper end of the marketing range, in another positive step for the recovery of the US IPO market. Late on Thursday, Patheon priced its IPO at US$21 a share, the upper end of the US$19-$22 indicative range. Debuting on the NYSE, the shares opened at US$25 before closing their first session just shy of that mark at US$24.99.